WO2000018730A1 - Novel compounds - Google Patents
Novel compounds Download PDFInfo
- Publication number
- WO2000018730A1 WO2000018730A1 PCT/SE1999/001632 SE9901632W WO0018730A1 WO 2000018730 A1 WO2000018730 A1 WO 2000018730A1 SE 9901632 W SE9901632 W SE 9901632W WO 0018730 A1 WO0018730 A1 WO 0018730A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- butoxy
- biphenyl
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
Definitions
- This invention relates to novel pyridyl derivatives, their use as medicaments, pharmaceutical formulations including them and methods for their preparation.
- PCT patent application WO 97/20815 discloses certain pyridine alkanol derivatives and their activity as mast cell antagonists.
- the present invention therefore provides a compound of formula (I) or a salt thereof:
- R is hydrogen or fluoro, preferably R is fluoro.
- R is fluoro.
- the fluoro group is ortho with respect to the sulfonamide group.
- n 1
- Particularly preferred compounds of the invention include: (2R)-3-Fluoro-4'-(2-hydroxy-4-pyridin-3-yl-butoxy)-biphenyl-4-sulfonic acid amide,
- Compounds of the invention can form pharmaceutically acceptable solvates and salts.
- the compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, trifluoroacetic and methanesulphonic acids.
- acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, trifluoroacetic and methanesulphonic acids.
- Compounds of the invention may also form alkali metal salts such as magnesium, sodium, potassium and calcium salts.
- Certain compounds of formula (I) are capable of existing in stereoisomeric forms including enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates.
- the different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis.
- the invention also extends to any tautomeric forms and mixtures thereof.
- the compounds of formula (I) have the following stereochemistry:
- R is as defined in formula (I), R is a hydroxy protecting group, and one of R -"£//R!_ •> is triflate or halo and the other is B(OH) 2 , or ZnHal, or
- Reaction of compounds of formulae (II) and (HI) can be carried out under the conditions of the Suzuki reaction (Synthetic Communications 1 1(7), 513-519, 1981) for example at ⁇ 100 °C in the presence of a suitable catalyst and base (e.g. tetrakis(triphenylphosphine)- palladium(O) and aqueous sodium carbonate) in a suitable solvent (e.g. ethanol/toluene).
- a suitable catalyst and base e.g. tetrakis(triphenylphosphine)- palladium(O) and aqueous sodium carbonate
- a suitable solvent e.g. ethanol/toluene
- Process (b) is carried out at elevated temperature, for example at about 60°C, in the presence of suitable base (e.g. cesium carbonate) and an appropriate organic solvent (e.g. dimethylformamide).
- suitable base e.g. cesium carbonate
- organic solvent e.g. dimethylformamide
- Processes (c) is carried out under the conditions of the Mitsonobu reaction, for example at approximately 0-25 °C in the presence of diethyl azodicarboxylate and triphenylphosphine in an appropriate solvent (e.g. toluene).
- an appropriate solvent e.g. toluene
- R 2 is B(OH)
- R 2 is bromine or iodine
- an appropriate solvent e.g. tetrahydrofuran
- low temperature e.g. - 78°C
- R" is bromine or iodine
- compounds of formula (VI) as defined above by reaction with a compound of formula (VII), in which R is bromine or iodine
- R 1 is as defined above using conventional procedures, for example hydrogenation using a palladium catalyst in an inert solvent such as ethyl acetate, followed by debenzylation using conventional methods such as those described in Protective Groups in
- M is lithium, sodium, potassium, MgX or ZnX, where X is halogen, optionally in the presence of additives such as boron trifluoride.
- Functional groups which it is desirable to protect include hydroxy and sulfonamide.
- Suitable protecting groups for hydroxy include organosilyl groups (e.g. - tert-butyldimethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl), benzyl and tetrahydro- pyranyl.
- a suitable protecting group for sulfonamide would be tertiary butyl. The protection and deprotection of functional groups may take place before or after a reaction step.
- Novel intermediates form a further aspect of the invention.
- Diastereoisomers may be separated using conventional techniques, e.g. chromatography or fractional crystallisation.
- the various optical isomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques.
- the compounds of the invention are useful because they possess pharmacological activity and more particularly activity in the modulation of inflammatory and allergic conditions, for example as shown in the test described below.
- the compounds of the invention inhibit the activation of a range of cell types from haematopoetic lineage, including mast cells, neutrophils and eosinophils.
- the invention therefore provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in therapy.
- the compounds of the invention are indicated for use in the treatment or prevention of allergic, inflammatory, auto-immune, proliferative and hyper-proliferative diseases.
- the compounds of the invention are also indicated in the treatment and prevention of allergic, inflammatory or auto-immune conditions of the lung, including reversible obstructive airways diseases which includes asthma (e.g. bronchial, allergic, intrinsic asthma, extrinsic and chronic asthma), and associated manifestations of the disease (late responses, hyper-responsiveness), also farmer's lung and related diseases, fibrosis, ideopathic interstitial pneumonia, chronic obstructive airways disease (COPD), bronchiectasis, cystic fibrosis, eosinophilic pneumonias, adult respiratory distress syndrome (ARDS), emphysema and alveolitis, for example cryptogenic fibrosing alveolrtis.
- asthma e.g. bronchial, allergic, intrinsic asthma, extrinsic and chronic asthma
- associated manifestations of the disease late responses, hyper-responsiveness
- COPD chronic obstructive airways disease
- COPD chronic obstructive airways disease
- the compounds of the invention are indicated in the treatment or prevention of allergic, inflammatory or auto-immune conditions in the nose including all conditions characterised by inflammation of the nasal mucous membrane such as acute rhinitis, allergic rhinitis, atrophic rhinitis, chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta and rhinitis sicca, rhinitis medicamentosa, membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis, scrofulous rhinitis, seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis.
- rhinitis and seasonal rhinitis including rhinitis nervosa (hay fever).
- the compounds are also indicated for the treatment of nasal polyps and allergic menifestations of the nasopharynx other than those described hereintofore.
- the compounds of the invention are also indicated the treatment or prevention of allergic, inflammatory or auto-immune conditions of the eye such as conjunctivitis (allergic, acute, vernal, of hay fever, chronic), inflammation disorders of the eyelids, cornea, uveal tract and retina.
- conjunctivitis allergic, acute, vernal, of hay fever, chronic
- inflammation disorders of the eyelids cornea, uveal tract and retina.
- the compounds of the invention are also indicated in the treatment and prevention of allergic, inflammatory and auto-immune conditions of the gastrointestinal tract such as food allergy and food intolerance, ulcerative colitis, Crohn's disease, irritable bowel disease, gastric ulcers, and food related allergic diseases which have symptomatic manifestations remote from the gastrointestinal tract, for example migraine, rhinitis and eczema.
- the compounds of the invention are indicated for use in the treatment or prevention of allergic, inflammatory or auto-immune conditions of the skin such as psoriasis, atopical dermatitis, contact dermatitis/dermatitis herpetiformis, erythema nodosum, urticaria, cutaneous eosinophilias, acne, Alopecia areata, eosinophilic fascitis dermatomyositis, photoallergic sensitivity and periodontal disease.
- allergic, inflammatory or auto-immune conditions of the skin such as psoriasis, atopical dermatitis, contact dermatitis/dermatitis herpetiformis, erythema nodosum, urticaria, cutaneous eosinophilias, acne, Alopecia areata, eosinophilic fascitis dermatomyositis, photoallergic sensitivity and periodontal disease.
- the compounds of the invention are therefore indicated for use in the treatment or prevention of allergic, inflammatory or auto-immune conditions of the joints and connective tissue, including osteoarthritis, rheumatoid arthritis, systemic lupus erythematosis, vasculitis, Wegener's granulomatosis, polyarthritis nodosa, bursitis. tendonitis, gout, Behcet's syndrome, ankylosing sponditis, Reiter's syndrome and psoriatic arthritis.
- the compounds of the invention are indicated in the treatment and prevention of allergic, inflammatory, and auto-immune conditions of the circulatory system including atheroma. reperfusion injury (e.g. on angioplasty), myocardial infarction, thrombosis and vascular and tissue damage caused by ischaemic disease or injury.
- the compounds of the invention are indicated in the treatment and prevention of allergic. inflammatory or auto-immune conditions of the CNS including Parkinson's disease, Alzheimers and other dementias, stroke and subarachnoid haemorrhage.
- the compounds of the invention are indicated in the treatment and prevention of inflammatory conditions of the liver for example hepatitis, cirrhosis and glomerulonephritis.
- the compounds of the invention are indicated in the treatment and prevention of allergic, inflammatory or auto-immune conditions of the bladder and uro-genital tract including cystitis.
- the compounds of the invention are indicated in the treatment and prevention of tumours and other proliferative diseases.
- a compound of formula I as hereinbefore defined, or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of the above diseases, in particular reversible obstructive airways disease.
- Administration of the compounds of the invention may be topical (for example by inhalation to the lung).
- the compounds of the invention may be inhaled as a dry powder which may be pressurised or non-pressurised.
- the active ingredient in finely divided form may be used in admixture with a larger sized pharmaceutically acceptable inert carrier.
- the composition may alternatively be pressurised and contain a compressed gas, e.g. nitrogen, or a liquefied gas propellant.
- a compressed gas e.g. nitrogen
- a liquefied gas propellant e.g. a liquefied gas propellant
- the active ingredient is preferably finely divided.
- the pressurised composition may also contain a surface active agent.
- the pressurised compositions may be made by conventional methods.
- the compounds of the invention may be administered systemically (for example by oral administration to the gastrointestinal tract).
- the active ingredient may be formulated together with known adjuvants, diluents or carriers using conventional techniques to produce tablets or capsules for oral administration to the gastrointestinal tract.
- Suitable adjuvants, diluents or carriers for oral administration in the form of tablets, capsules and dragees include microcrystalline cellulose, calcium phosphate, diatomaceous earth, a sugar such as lactose, dextrose or mannitol, talc, stearic acid, starch, sodium bicarbonate and/or gelatin.
- a pharmaceutical composition including a compound of formula I or a salt or solvate thereof as hereinbefore defined in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
- Suitable doses for such oral administration are in the range from 0.03 to 30 mg kg "1 day “1 , for example 0.3 mg kg "1 day “1 .
- a method of treatment or prophylaxis of a reversible obstructive airways disease, in particular asthma which method comprises administration of a therapeutically effective amount of a compound of formula I as hereinbefore defined, or a pharmaceutically acceptable derivative thereof, to a person suffering from, or susceptible to, the disease.
- hydrochloride salt was prepared in a similar manner from (3R)-3-[3-(tert-Butyl- dimethylsilyloxy)-4-(4'-fluoro-3'-methyl-biphenyl-4-yloxy)-butyl]-pyridine (Example li, 0.935g), the hydrochloride salt being filtered from the reaction mixture, washed with diethyl ether and dried to afford the title compound as a white solid (0.802g). MS (APCI) + 417 ((M-HC1)+H) +
- 4-Bromo-3-fluoroaniline (3.49 g, WO9216519) was suspended in concentrated hydrochloric acid (30 ml) and stirred at room temperature for 17 hours. The suspension was cooled to -5 °C and a solution of sodium nitrite (1.42 g) in water (15 ml) was added dropwise at such a rate to maintain the temperature below 0 °C. Magnesium chloride (2.94 g) was added portionwise maintaining the temperature below 0 °C. The resulting mixture was added with stirring to a saturated solution of sulfur dioxide in acetic acid (40 ml), containing cupric chloride (0.98 g) at room temperature.
- Example li Prepared according to the method described in Example li from (2R)- 4-[4-(3-pyridyl)-2-(tert-butyldimethylsilyloxy)butoxy]benzene boronic acid (Example lg, 0.250g), 4-bromo-2,6-difluorobenzenesulfonamide, (Example 4a, 0.254g), tetr ⁇ / ⁇ striphenylphosphine palladium (0) (0.018g), aqueous 2 molar sodium carbonate (0.72ml) and ethanol (3ml). The reaction was refluxed in a sealed Wheaton vial for ten hours at 90°C.
- Example li Prepared according to the method described in Example li) from (2R)- 4-[4-(3-pyridyl)-2-(tert-butyldimethylsilyloxy)butoxy]benzene boronic acid (Example lg, 0.265g), 4-bromobenzenesulfonamide (0.312g), tetra/ ⁇ striphenylphosphine palladium (0) (0.020g), aqueous 2 molar sodium carbonate (0.66ml) and ethanol (3ml) with heating at 90°C for 4 hours. After work-up, the residue was purified by normal phase hplc, eluting with a gradient of 0 to 5% ethanol in dichloromethane.
- the white solid obtained was dissolved in methanol (5ml) and stirred with two molar hydrochloric acid (2ml) overnight at room temperature.
- the hydrochloride salt was filtered from the reaction mixture, washed with diethyl ether and dried to give the title compound as a white solid (0.06g).
- the pharmacological activity of the compounds of the invention may be tested by the method of E. Wells et al, 'Characterization of primate bronchoalveolar mast cells: II — inhibition of histamine, LTC 4 and PGD 2 release from primate bronchoalveolar mast cells " and a comparison with rat peritoneal mast cells', J. Immunol., vol. 137, 3941, 1986.
- the compounds exemplified were tested and found to inhibit histamine release at a concentration of less than 10 "4 M (IC 50 ).
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99969714A EP1115706A1 (en) | 1998-09-25 | 1999-09-17 | Novel compounds |
AU11923/00A AU1192300A (en) | 1998-09-25 | 1999-09-17 | Novel compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9803280A SE9803280D0 (en) | 1998-09-25 | 1998-09-25 | Novel compounds |
SE9803280-8 | 1998-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000018730A1 true WO2000018730A1 (en) | 2000-04-06 |
Family
ID=20412739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1999/001632 WO2000018730A1 (en) | 1998-09-25 | 1999-09-17 | Novel compounds |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1115706A1 (en) |
AU (1) | AU1192300A (en) |
SE (1) | SE9803280D0 (en) |
WO (1) | WO2000018730A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005115385A1 (en) * | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
US7329401B2 (en) | 2002-04-15 | 2008-02-12 | The Regents Of The University Of California | Cyclooxygenase-2 selective agents useful as imaging probes and related methods |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020815A1 (en) * | 1995-12-06 | 1997-06-12 | Astra Pharmaceuticals Ltd. | Compounds |
-
1998
- 1998-09-25 SE SE9803280A patent/SE9803280D0/en unknown
-
1999
- 1999-09-17 EP EP99969714A patent/EP1115706A1/en not_active Withdrawn
- 1999-09-17 AU AU11923/00A patent/AU1192300A/en not_active Abandoned
- 1999-09-17 WO PCT/SE1999/001632 patent/WO2000018730A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020815A1 (en) * | 1995-12-06 | 1997-06-12 | Astra Pharmaceuticals Ltd. | Compounds |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7329401B2 (en) | 2002-04-15 | 2008-02-12 | The Regents Of The University Of California | Cyclooxygenase-2 selective agents useful as imaging probes and related methods |
WO2005115385A1 (en) * | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
Also Published As
Publication number | Publication date |
---|---|
SE9803280D0 (en) | 1998-09-25 |
AU1192300A (en) | 2000-04-17 |
EP1115706A1 (en) | 2001-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7968724B2 (en) | Ester derivatives as phosphodiesterase inhibitors | |
EP0611003B1 (en) | Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity | |
JP2010535722A (en) | Derivatives of 1-phenyl-2-pyridinylalkyl alcohol as phosphodiesterase inhibitors | |
US6265409B1 (en) | Pyridine derivatives and pharmaceutical compositions containing them | |
EP0605031A1 (en) | Phenoxy- and phenoxyalkyl-piperidines as antiviral agents | |
AU711772B2 (en) | Compounds | |
US6300352B1 (en) | Pyridine derivatives and pharmaceutical compositions containing them | |
US6143751A (en) | Pyridine derivatives and pharmaceutical compositions containing them | |
US5143926A (en) | Substituted pyridine-2,4-dicarboxylic acid compounds and methods of use thereof | |
EP1115706A1 (en) | Novel compounds | |
EP0623597B1 (en) | Pyridine derivatives, with potassium channel opening activity | |
US5118691A (en) | Substituted tetrahydropyridines as central nervous system agents | |
EP1115401A1 (en) | Novel compounds | |
ZA200101759B (en) | Novel compounds. | |
WO2000018736A1 (en) | Novel compounds | |
ES2275917T3 (en) | 2-AMINO-6- (PHENYL-2,4,5-SUBSTITUTED) -PIRIDINES TO USE AS INHIBITORS OF NITRICO SINTASA OXIDE. | |
CZ349999A3 (en) | Novel pyridine derivatives and pharmaceutical preparations containing thereof | |
US20040077853A1 (en) | 2-amino-6-(2,4,5-substituted-phenyl)-pyridines | |
WO2000056714A1 (en) | Novel compounds | |
CZ343699A3 (en) | Novel pyridine derivatives and pharmaceutical preparations containing thereof | |
MXPA01002293A (en) | Novel compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 09403895 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 11923 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999969714 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999969714 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999969714 Country of ref document: EP |